FI106044B - Förfarande för framställning av en däggdjurs-IL-4-receptor (IL-4R) och dess motkropp och DNA som kodar för IL-4R, vektor och värdcell - Google Patents
Förfarande för framställning av en däggdjurs-IL-4-receptor (IL-4R) och dess motkropp och DNA som kodar för IL-4R, vektor och värdcell Download PDFInfo
- Publication number
- FI106044B FI106044B FI912064A FI912064A FI106044B FI 106044 B FI106044 B FI 106044B FI 912064 A FI912064 A FI 912064A FI 912064 A FI912064 A FI 912064A FI 106044 B FI106044 B FI 106044B
- Authority
- FI
- Finland
- Prior art keywords
- groups
- sequence
- dna
- receptor
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Claims (18)
1. Isolerad DNA, vilken koodar för en däggdjurs-IL-4-receptor (IL-4R),kännetecknad av att den 5 väljs frän en grupp bestäende av: (a) cDNÄ-kloner som omfattar en nukleotidsekvens som visas i figurerna 2A - 2C som nukleotiderna -75 - 2355, i figurerna 2A - 2C som nukleotiderna 1 - 2355, i figurerna 4A - 4C som nukleotiderna -75 - 2400 eller i fi- 10 gurerna 4A - 4C som nukleotiderna 1 - 2400; (b) DNA-sekvenser, vilka förmär hybridisera med cDNA i punkt (a) under tämligen stringenta förhällanden och vilka kodar för en polypeptid, som förmär binda ett däggdjurs-IL-4; och 15 (c) DNA-sekvenser, vilka är degenererade som ett resultat av den genetiska koden i förhällande tili den punkt i (a) eller (b) definierade DNA-sekvensen, och vilka kodar för en polypeptid, som förmär binda ett däggdjurs-IL-4.
2. DNA enligt patentkrav 1, känneteck- n a d av att IL-4R väsentligen bestär av mus-IL-4R.
3. DNA enligt patentkrav 1, känneteck-nad av att IL-4R väsentligen bestär av människo1IL-4R.
4. DNA enligt patentkrav 1, känneteck- • »· 25 nad av att IL-4R omf attar en aminosyrasekvens, som är över 80 % identisk med aminosyrasekvensen i figurerna 2A -2C eller 4A - 4C.
5. DNA enligt patentkrav 1, känneteck-n a d av att IL - 4R är lösligt IL-4R, som omfattar en 30 aminosyrasekvens som är över 80 % identisk med sekvensen hos de i figur 4A förevisade grupperna 1 - 207.
6. DNA enligt patentkrav 2 eller 3, k ä n n e -tecknade av att IL-4R är ett fragment av mus-IL-4R-proteinet som visas i figurerna 2A - 2C, eller ett 35 fragment av människo-IL-4R-proteinet som visas i figurerna 4A - 4C, vilka fragment kan binda IL-4. 106044
7. DNA enligt patent krav 2, känneteck- n a d av att IL-4R omfattar en aminosyrasekvens, som är sekvensen av grupperna -25 - 785 i figurerna 2A - 2C, grupperna 1 - 785 i figurerna 2A - 2C, grupperna -25 - 208 5. figur 2A eller grupperna 1 - 208 i figur 2A.
8. DNA enligt patent krav 3, känneteck- n a d av att IL-4R omfattar en aminosyrasekvens, som är sekvensen av grupperna -25 - 800 i figurerna 4A - 4C, grupperna 1 - 800 i figurerna 4A - 4C, grupperna -25 - 207 10. figur 4A eller grupperna 1 - 207 i figur 4A.
9. DNA sekvens enligt patentkrav 3, k ä n n e -tecknad av att den omfattar nukleotiderna -75 -621 eller 1 - 621 i figur 4A.
10. Rekombinant expressionsvektor, kanne-15 tecknad av att den omfattar en DNA enligt nägät av patentkraven 1-9.
11. Värdcell, kännetecknad av att den omfattar en expressionsvektor enligt patentkrav 10.
12. Förfarande för framställning av en IL-4R-20 polypeptid, kännetecknad av att man odlar en värdcell enligt patentkrav 11 under förhällanden som be-främjar expression av IL-4R-polypeptiden, varefter IL-4R-polypeptiden renas.
13. Förfarande enligt patentkrav 12, kanne-25 t e c k n a t av att IL-4R väsentligen bestär av mus-IL- 4R eller människo-IL-4R.
14. Förfarande enligt patentkrav 13, k ä n n e-tecknat av att IL-4R omfattar en aminosyrasekvens, som är sekvensen av grupperna 1 - 800 i figurerna 4A - 4C 30 eller grupperna 1 - 207 i figur 4A.
15. Förfarande enligt patentkrav 13, k ä n n e -tecknat av att expressionsvektorn omfattar nukleotiderna -75 - 621 i figur 4A.
16. Förfarande för att producers antikroppar, vil-35 ka är immunoreaktiva med IL-4R, kännetecknat av att man immuniserar ett djur med en I1-4R polypeptid ··< 106044 och tar tillvara antikroppar av det immuniserade djuret, varvid antikropparna är immunoreaktiva med ett IL-4R, som omfattar en aminosyrasekvens, som är sekvensen av grupper-na 1 - 785 i figurerna 2A-2C, grupperna 1 - 208 i figur 5 2A, grupperna 1 - 800 i figurerna 4A-4C eller grupperna 1 - 207 i figur 4A.
17. Förfarande för att producera en monoklonal an-tikropp, vilken är immunoreaktiv med IL-4R, k ä n n e -tecknat av att 10 (a) man immuniserar ett djur med en IL-4R- polypeptid, (b) man deponerar mjältceller av det immuniserade djuret, (c) man fusionerar de tillvaratagna mjältcellerna 15 med en myelomacell-linje, varigenom hybridomcell-linjer produceras. (d) man identifierar enhybridomcell-linje, som producerar monoklonala antikroppar som är immunoreaktiva med IL-4R 20 (e) man tar tillvara de monoklonala antikropparna, varvid de monoklonala antikropparna är immunoreaktiva med IL-4R, som omfattar en aminosyrasekvens, som är sekvensen av grupperna 1 - 785 i figurerna 2A-2C, grupperna 1 - 208 i figur 2A, grupperna 1 - 800 i figurerna 4A-4C eller »· · • 25 grupperna 1 - 207 i figur 4A.
18. Förfarande enligt patentkrav 16 eller 17, kännetecknat av att antikropparna är immunoreaktiva med IL-4R, som omfattar en aminosyrasekvens som är sekvensen av av grupperna 1 - 800 i figurerna 4A-4C eller 30 grupperna 1 - 207 i figur 4A. • ·
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26504788A | 1988-10-31 | 1988-10-31 | |
US26504788 | 1988-10-31 | ||
US31943889A | 1989-03-02 | 1989-03-02 | |
US31943889 | 1989-03-02 | ||
US32615689A | 1989-03-20 | 1989-03-20 | |
US32615689 | 1989-03-20 | ||
US37092489A | 1989-06-23 | 1989-06-23 | |
US37092489 | 1989-06-23 | ||
PCT/US1989/004076 WO1990005183A1 (en) | 1988-10-31 | 1989-09-18 | Interleukin-4 receptors |
US8904076 | 1989-09-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
FI912064A0 FI912064A0 (fi) | 1991-04-29 |
FI106044B true FI106044B (sv) | 2000-11-15 |
Family
ID=27500837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI912064A FI106044B (sv) | 1988-10-31 | 1991-04-29 | Förfarande för framställning av en däggdjurs-IL-4-receptor (IL-4R) och dess motkropp och DNA som kodar för IL-4R, vektor och värdcell |
Country Status (14)
Country | Link |
---|---|
US (10) | US5840869A (sv) |
EP (1) | EP0367566B1 (sv) |
JP (1) | JP2744821B2 (sv) |
AT (1) | ATE153068T1 (sv) |
AU (1) | AU643427B2 (sv) |
DE (1) | DE68928043T2 (sv) |
DK (1) | DK175583B1 (sv) |
ES (1) | ES2103706T3 (sv) |
FI (1) | FI106044B (sv) |
GR (1) | GR3024271T3 (sv) |
IE (1) | IE61013B1 (sv) |
IL (1) | IL91705A (sv) |
NZ (1) | NZ231189A (sv) |
WO (1) | WO1990005183A1 (sv) |
Families Citing this family (274)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005183A1 (en) * | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
JPH04504061A (ja) * | 1989-09-07 | 1992-07-23 | シェリング・コーポレーション | インターロイキン―4レセプター |
DK0939121T4 (da) | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
WO1991007186A1 (en) * | 1989-11-21 | 1991-05-30 | The University Of Melbourne | Anti-inflammatory compositions and methods |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
US20030064480A1 (en) * | 1990-06-28 | 2003-04-03 | Leander Lauffer | Fusion proteins with immunoglobulin portions, the preparation and use thereof |
US5453491A (en) * | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
WO1993007863A1 (en) * | 1991-10-15 | 1993-04-29 | Mullarkey Michael F | Methods and compositions for treating allergic reactions |
JPH07505047A (ja) * | 1991-11-27 | 1995-06-08 | シェリング・コーポレーション | ヒトインターロイキン−4受容体の細胞質ドメインの,il−4のアンタゴニストとしての部分 |
DE4322330A1 (de) | 1992-08-31 | 1994-03-03 | Behringwerke Ag | Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen |
US5714146A (en) * | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
DE4228839A1 (de) * | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
EP0604693A1 (en) * | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
CA2157785A1 (en) * | 1993-03-19 | 1994-09-29 | Immunex Corporation | Pharmaceutical compositions comprising soluble interleukin-4 receptor and interleukin-4 |
US5470952A (en) * | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
US5591825A (en) * | 1994-07-05 | 1997-01-07 | Tularik, Inc. | Interleukin 4 signal transducers |
US20020028798A1 (en) * | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
US7091181B2 (en) | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
ES2253753T3 (es) | 1995-06-29 | 2006-06-01 | Immunex Corporation | Citocina que induce apoptosis. |
US6541604B1 (en) * | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
US20050019325A1 (en) * | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
US7074397B1 (en) * | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
US7078494B1 (en) * | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
US20060205660A1 (en) * | 1996-06-20 | 2006-09-14 | Sauvage Frederic D | OB protein-immunoglobulin chimeras |
US6586210B1 (en) * | 1996-08-23 | 2003-07-01 | Human Genome Sciences, Inc. | Polynucleotides encoding T1 receptor like ligand II |
US6605271B2 (en) * | 1996-08-23 | 2003-08-12 | Human Genome Sciences, Inc. | T1 receptor-like ligand II and uses thereof |
DE69738841D1 (de) | 1996-12-23 | 2008-08-28 | Immunex Corp | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
CA2306450C (en) * | 1997-10-29 | 2012-07-10 | Genentech, Inc. | Polypeptides and nucleic acids encoding same |
US6703488B1 (en) * | 1998-01-15 | 2004-03-09 | Center For Molecular Medicine And Immunology | Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
WO1999045777A1 (en) * | 1998-03-10 | 1999-09-16 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of asthma |
NZ510497A (en) | 1998-08-21 | 2003-09-26 | Immunex Corp | Human IL-1 epsilon DNA and polypeptides |
EP1939297A1 (en) | 1998-09-24 | 2008-07-02 | Pharmacia & Upjohn Company LLC | Alzheimer's disease secretase |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US7067144B2 (en) * | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
US7553487B2 (en) * | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
AU780031B2 (en) * | 1998-12-14 | 2005-02-24 | Genetics Institute, Llc | Cytokine receptor chain |
US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
US6693172B1 (en) | 1999-05-27 | 2004-02-17 | Pharmacia And Upjohn Company | Double mutant alpha-7 nicotinic acetylcholine receptor |
US6455290B1 (en) | 1999-07-09 | 2002-09-24 | Pharmacia Italia S.P.A. | Tankyrase homolog protein (THP), nucleic acids, and methods related to the same |
WO2001004270A1 (en) * | 1999-07-13 | 2001-01-18 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the interleukin 4 receptor alpha gene |
JP2003512838A (ja) | 1999-10-22 | 2003-04-08 | ファルマシア・アンド・アップジョン・カンパニー | ショウジョウバエgタンパク質結合レセプター、核酸、およびそれに関連する方法。 |
AU2077801A (en) * | 1999-12-10 | 2001-06-18 | Human Genome Sciences, Inc. | T1 receptor-like ligand ii and uses thereof |
ES2433011T3 (es) | 1999-12-20 | 2013-12-05 | Immunex Corporation | Receptor TWEAK |
US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
US6498026B2 (en) | 2000-02-25 | 2002-12-24 | Hercules Incorporated | Variant galactose oxidase, nucleic acid encoding same, and methods of using same |
EP2241328A1 (en) | 2000-05-12 | 2010-10-20 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
EP1158058A1 (en) * | 2000-05-19 | 2001-11-28 | Centre National De La Recherche Scientifique | Compositions and methods suitable for nucleic acid analyses |
EP1297112A2 (en) | 2000-05-22 | 2003-04-02 | PHARMACIA & UPJOHN COMPANY | Novel matrix metalloproteinases |
ES2614260T3 (es) | 2000-05-26 | 2017-05-30 | Immunex Corporation | Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos |
US7259244B2 (en) | 2000-06-16 | 2007-08-21 | Nerviano Medical Sciences S.R.L. | Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same |
US6686449B2 (en) | 2000-06-30 | 2004-02-03 | Pharmacia & Upjohn Company | Mutant presenilin 1 polypeptides |
AU2001271839A1 (en) | 2000-07-05 | 2002-01-14 | Pharmacia And Upjohn Company | Human ion channels |
AU2001273413A1 (en) * | 2000-07-12 | 2002-01-21 | Immunex Corporation | Method for treating cancer using an interleukin- 4 antagonist |
US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
ATE355849T1 (de) * | 2000-12-21 | 2007-03-15 | Nektar Therapeutics | Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor |
PL232477B1 (pl) * | 2001-09-20 | 2019-06-28 | Immunex Corp | System ekspresji gospodarza i sposób wytwarzania heteromerycznego kompleksu |
CA2462790A1 (en) | 2001-10-04 | 2003-04-10 | Immunex Corporation | Ul16 binding protein 4 |
US20050112616A1 (en) * | 2001-12-10 | 2005-05-26 | William Lee | Functionalized materials and libraries thereof |
PL376821A1 (pl) | 2002-03-27 | 2006-01-09 | Immunex Corporation | Sposoby zwiększania produkcji polipeptydów |
ATE353954T1 (de) * | 2002-10-11 | 2007-03-15 | Sentoclone Therapeutics Ab | Immuntherapie für krebs |
WO2004034988A2 (en) | 2002-10-16 | 2004-04-29 | Amgen Inc. | Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors |
ES2571355T3 (es) | 2002-12-16 | 2016-05-24 | Technion Res & Dev Foundation | Sistema de cultivo sin células alimentadoras ni xenocontaminantes para células madre embrionarias humanas |
BRPI0406776A (pt) * | 2003-01-18 | 2005-12-27 | Childrens Hosp Medical Center | Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß |
EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
MXPA06000974A (es) | 2003-07-25 | 2006-08-31 | Amgen Inc | Antagonistas y agonistas de ldcam y metodos para su uso. |
TWI356064B (en) | 2003-11-07 | 2012-01-11 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
SG10201900535UA (en) * | 2003-12-23 | 2019-02-27 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
JP2008504806A (ja) | 2004-02-27 | 2008-02-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il−4/il−13特異的ポリペプチドおよびその治療上の使用 |
EP1730174B1 (en) | 2004-03-05 | 2010-04-21 | The Board Of Trustees Of The University Of Illinois | Peptide carrier for drug delivery |
US7319015B2 (en) | 2004-03-16 | 2008-01-15 | The Regents Of The University Of Michigan | Methods and compositions for using alveolar macrophage phospholipase A2 |
US7582442B2 (en) | 2004-03-16 | 2009-09-01 | The Regents Of The University Of Michigan | Methods and compositions for using aleveolar macrophage phospholipase A2 |
JP2007530045A (ja) * | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | ヒトox40l(cd134l)特異性モノクローナル抗体 |
WO2005116069A2 (en) | 2004-04-14 | 2005-12-08 | Monell Chemical Senses Center | Taste receptors of the t1r family from domestic dog |
ES2570665T3 (es) | 2004-04-23 | 2016-05-19 | Zoetis Services Llc | Factor de permisividad celular para virus, y usos del mismo |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
ES2408704T3 (es) | 2005-01-05 | 2013-06-21 | Biogen Idec Ma Inc. | Moléculas de unión a Cripto |
EP1909831A4 (en) * | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
US20070009479A1 (en) * | 2005-06-17 | 2007-01-11 | Aerovance, Inc. | Methods for treating dermatitis using mutant human IL-4 compositions |
KR20070009269A (ko) | 2005-07-15 | 2007-01-18 | 한국생명공학연구원 | 재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자 |
JP2009516513A (ja) * | 2005-11-21 | 2009-04-23 | ラボラトワール セローノ ソシエテ アノニム | ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用 |
JP5205275B2 (ja) * | 2005-12-21 | 2013-06-05 | セントクローネ インターナショナル エービー | 散在性ガンの治療法 |
US8101173B2 (en) * | 2005-12-21 | 2012-01-24 | Sentoclone International Ab | Method for treating urinary bladder cancer |
AU2006328943B2 (en) * | 2005-12-21 | 2011-07-21 | Sentoclone International Ab | Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer |
WO2007071390A1 (en) * | 2005-12-21 | 2007-06-28 | Sentoclone Ab | Method for treating malignant melanoma |
US8129334B2 (en) | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
JP2010514409A (ja) | 2006-06-21 | 2010-05-06 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヒトの癌における鑑別式サイトカイン発現 |
CA2656135A1 (en) * | 2006-07-06 | 2008-01-10 | Apogenix Gmbh | Human il-4 muteins in cancer therapy |
JP5577543B2 (ja) | 2006-09-08 | 2014-08-27 | アムジエン・インコーポレーテツド | Il−1ファミリーバリアント |
AU2007294731B2 (en) | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
EP2500415A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
RU2445318C2 (ru) | 2006-10-02 | 2012-03-20 | Ридженерон Фармасьютикалз, Инк. | Высокоаффинные антитела человека к рецептору il-4 человека |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
TW200848429A (en) * | 2007-04-23 | 2008-12-16 | Wyeth Corp | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
BRPI0815368A2 (pt) | 2007-08-21 | 2015-02-10 | Amgen Inc | "proteinas c-fms humanas a antigeno" |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
EP3211010A1 (en) * | 2007-12-21 | 2017-08-30 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (il-4r) - 173 |
US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
GB0803076D0 (en) | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof |
CA2722466A1 (en) | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
EP2113262B1 (en) * | 2008-04-29 | 2013-11-06 | Proxy Biomedical Limited | A Tissue Repair Implant |
AU2009256250B2 (en) | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2725666A1 (en) | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
US8052970B2 (en) | 2008-06-30 | 2011-11-08 | The Regents Of The University Of Michigan | Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis |
NZ590074A (en) | 2008-07-08 | 2012-12-21 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
WO2010006808A1 (en) * | 2008-07-18 | 2010-01-21 | Sentoclone Ab | Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer |
EP2328908A4 (en) | 2008-08-28 | 2012-11-28 | Univ New York State Res Found | TREATMENT OF AMYLOIDOSES BASED ON MYELIN BASED PROTEIN AND FRAGMENTS THEREOF |
EP2370470B1 (en) | 2008-12-04 | 2016-10-05 | Korea Research Institute of Bioscience and Biotechnology | Screening of abundantly secreted proteins and their use as fusion partners for the production of recombinant proteins |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
US20120076754A1 (en) | 2009-05-20 | 2012-03-29 | Ziad Mallat | Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
US20120311728A1 (en) | 2009-11-06 | 2012-12-06 | Ziad Mallat | Methods and pharmaceutical composition for the treatment of atherosclerosis |
US8759293B2 (en) | 2009-11-13 | 2014-06-24 | Grifols Therapeutics Inc. | von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
ES2477498T3 (es) | 2010-01-20 | 2014-07-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Proteína 4 del tipo angiopoyetina (ANGPTL4) para el mantenimiento de la integridad de la barrera celular del endotelio vascular |
EP2556086B1 (en) | 2010-04-09 | 2015-03-04 | Amgen Inc. | Btnl9 proteins, nucleic acids, and antibodies and uses thereof |
EP2558497A2 (en) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
EP2591006B1 (en) | 2010-07-09 | 2019-04-24 | Bioverativ Therapeutics Inc. | Processable single chain molecules and polypeptides made using same |
CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
SG187198A1 (en) | 2010-08-05 | 2013-03-28 | Amgen Inc | Dipeptides to enhance yield and viability from cell cultures |
TW201211252A (en) | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2621511A1 (en) | 2010-09-28 | 2013-08-07 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of bone density related diseases |
CA2828405A1 (en) | 2011-02-28 | 2012-09-07 | Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale | Apoptosis-inducing molecules and uses therefor |
ES2668895T3 (es) | 2011-03-16 | 2018-05-23 | Amgen Inc. | Variantes de Fc |
WO2012145682A1 (en) | 2011-04-21 | 2012-10-26 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
ES2560012T3 (es) | 2011-05-10 | 2016-02-17 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
EP2535714A1 (en) * | 2011-06-16 | 2012-12-19 | Istituto Nazionale Di Genetica Molecolare-INGM | Biomarkers for autoimmune liver diseases and uses thereof |
CN107988166B (zh) | 2011-07-01 | 2022-03-15 | 美国安进公司 | 哺乳动物细胞培养 |
WO2013009971A1 (en) | 2011-07-12 | 2013-01-17 | E. I. Du Pont De Nemours And Company | Detection and screening method and materials useful in performance thereof |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
EA201490555A1 (ru) | 2011-09-02 | 2014-07-30 | Эмджен Инк. | Фармацевтический продукт и способ анализа реакции фармацевтического продукта на свет |
KR102007055B1 (ko) | 2011-09-22 | 2019-08-02 | 암젠 인크 | Cd27l 항원 결합 단백질 |
WO2013050441A1 (en) | 2011-10-05 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation |
EP2596802A1 (en) | 2011-11-23 | 2013-05-29 | PLS-Design GmbH | Pharmaceutical composition for treatment of allergic reactions |
ES2638649T3 (es) | 2011-11-28 | 2017-10-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Composición farmacéutica para su uso en el tratamiento de disfunciones asociadas al envejecimiento |
TW201329104A (zh) | 2011-12-08 | 2013-07-16 | Amgen Inc | 人類lcat抗原結合蛋白質及其治療用途 |
AR089231A1 (es) | 2011-12-15 | 2014-08-06 | Amgen Inc | Metodo de floculacion |
UY34558A (es) | 2011-12-30 | 2013-07-31 | Abbvie Inc | Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17 |
PL2802606T3 (pl) | 2012-01-10 | 2018-09-28 | Biogen Ma Inc. | Udoskonalenie transportu cząsteczek terapeutycznych przez barierę krew-mózg |
HUE053362T2 (hu) | 2012-04-27 | 2021-06-28 | Novo Nordisk As | Emberi CD30-ligand antigént kötõ fehérjék |
AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
CN104519898A (zh) | 2012-06-06 | 2015-04-15 | 国家健康与医学研究院 | 用于治疗癌症的方法和药物组合物 |
EP2674168A1 (en) | 2012-06-14 | 2013-12-18 | PLS-Design GmbH | Modulation of effector T cell responses by local depletion of complement component C3 |
AU2013292510A1 (en) | 2012-07-19 | 2015-02-05 | Amgen Inc. | Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof |
CN110624107A (zh) | 2012-08-21 | 2019-12-31 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗或预防哮喘的方法 |
US9309318B2 (en) | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US9783789B2 (en) | 2012-12-07 | 2017-10-10 | North Carolina State University | Beta-hexosyl-transferases and uses thereof |
WO2014109858A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
TWI771890B (zh) | 2013-03-14 | 2022-07-21 | 美商安美基公司 | 用於增加重組蛋白質之甘露糖含量之方法 |
AU2014244444A1 (en) | 2013-03-14 | 2015-09-24 | Amgen Inc. | CHRDL-1 antigen binding proteins and methods of treatment |
EP4026596A1 (en) | 2013-03-14 | 2022-07-13 | Amgen, Inc | Removal of leaked affinity purification ligand |
AU2014228938B2 (en) | 2013-03-15 | 2019-05-02 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
WO2014144553A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment |
WO2014144632A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Human pac1 antibodies |
EP2970483A2 (en) | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
PL3456743T3 (pl) | 2013-05-30 | 2022-03-07 | Kiniksa Pharmaceuticals, Ltd. | Białka wiążące antygen receptora onkostatyny m |
US9481901B2 (en) | 2013-05-30 | 2016-11-01 | Amgen Inc. | Methods for increasing mannose content of recombinant proteins |
TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
PL3010539T3 (pl) | 2013-06-21 | 2020-01-31 | Sanofi Biotechnology | Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r |
TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
JP6668241B2 (ja) | 2013-09-05 | 2020-03-18 | アムジエン・インコーポレーテツド | 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すFc含有分子 |
WO2015038888A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Methods and compositions comprising purified recombinant polypeptides |
RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
WO2015048272A1 (en) | 2013-09-25 | 2015-04-02 | Amgen Inc. | V-c-fc-v-c antibody |
US11130980B2 (en) | 2013-10-31 | 2021-09-28 | Amgen Inc. | Use of monensin to regulate glycosylation of recombinant proteins |
WO2015086727A2 (en) | 2013-12-11 | 2015-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New prognostic method for patients suffering of a cancer |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
KR102381791B1 (ko) | 2014-01-13 | 2022-03-31 | 암젠 인크 | 재조합 단백질의 고수준 만노스 글리코폼 함량을 조작하기 위한 오르니틴 대사의 조절 |
SG10201912081RA (en) | 2014-01-29 | 2020-02-27 | Amgen Inc | Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
US10106829B2 (en) | 2014-01-29 | 2018-10-23 | Amgen Inc. | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
AU2015218903B2 (en) | 2014-02-20 | 2020-10-15 | Allergan, Inc. | Complement component C5 antibodies |
CA2940295A1 (en) | 2014-02-21 | 2015-08-27 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
KR20160126054A (ko) | 2014-02-27 | 2016-11-01 | 알러간, 인코포레이티드 | 보체 인자 Bb 항체 |
WO2015130975A1 (en) | 2014-02-28 | 2015-09-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
NO2785538T3 (sv) * | 2014-05-07 | 2018-08-04 | ||
EP3467501B1 (en) | 2014-05-16 | 2020-11-04 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
SG11201610143VA (en) | 2014-06-04 | 2017-01-27 | Amgen Inc | Methods for harvesting mammalian cell cultures |
WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
EP3194435A1 (en) | 2014-09-15 | 2017-07-26 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
KR20170081262A (ko) | 2014-11-14 | 2017-07-11 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법 |
MX2017006463A (es) | 2014-11-19 | 2018-04-20 | Amgen Inc | Cuantificacion de porcion de glicano en glicoproteinas recombinantes. |
WO2016089919A1 (en) | 2014-12-01 | 2016-06-09 | Amgen Inc. | Process for manipulating the level of glycan content of a glycoprotein |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
RU2017127609A (ru) | 2015-02-04 | 2019-03-04 | Ф. Хоффманн-Ля Рош Аг | Антисмысловые олигомеры тау-белка и их применение |
EP3254104B1 (en) | 2015-02-04 | 2021-08-25 | Bristol-Myers Squibb Company | Methods of selecting therapeutic molecules |
US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
JP6938383B2 (ja) | 2015-04-02 | 2021-09-22 | インターベット インターナショナル ベー. フェー. | イヌインターロイキン4受容体アルファに対する抗体 |
CA2980189A1 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
JP6932700B2 (ja) | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
EP3699269A1 (en) | 2015-09-22 | 2020-08-26 | F. Hoffmann-La Roche AG | Expression of fc-containing proteins |
WO2017079165A1 (en) | 2015-11-02 | 2017-05-11 | Genentech, Inc. | Methods of making fucosylated and afucosylated forms of a protein |
EP3390447A1 (en) | 2015-12-15 | 2018-10-24 | Amgen Inc. | Pacap antibodies and uses thereof |
WO2017112824A2 (en) | 2015-12-23 | 2017-06-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
KR20180133198A (ko) | 2016-05-04 | 2018-12-13 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
IL285146B (en) | 2016-07-22 | 2022-09-01 | Amgen Inc | Methods for purifying proteins involving fc |
JP2019531273A (ja) | 2016-09-01 | 2019-10-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−4rアンタゴニストを投与することによりアレルギーを予防又は処置するための方法 |
WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
BR112019007858A2 (pt) | 2016-10-21 | 2019-07-02 | Amgen Inc | formulações farmacêuticas e métodos para produzir as mesmas |
CA3043528A1 (en) | 2016-11-14 | 2018-05-17 | Amgen Inc. | Bispecific or biparatopic antigen binding proteins and uses thereof |
TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
CA3049110A1 (en) | 2017-01-06 | 2018-07-12 | Abl Bio Inc. | Anti-.alpha.-syn antibody and use thereof |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
EP3596225A1 (en) | 2017-03-14 | 2020-01-22 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
WO2018195388A1 (en) | 2017-04-21 | 2018-10-25 | Kindred Biosciences, Inc. | Il4/il13 receptor molecule for veterinary use |
JOP20190259A1 (ar) | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
EP3642239A1 (en) | 2017-06-20 | 2020-04-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
US11174322B2 (en) | 2017-07-24 | 2021-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat HCMV related diseases |
US20210346513A1 (en) | 2017-08-04 | 2021-11-11 | Amgen Inc. | Method of conjugation of cys-mabs |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
KR20200110362A (ko) | 2018-01-12 | 2020-09-23 | 암젠 인크 | Pac1 항체 및 이의 용도 |
EA202092286A1 (ru) | 2018-03-26 | 2021-03-18 | Эмджен Инк. | Общие афукозилированные гликоформы антител, полученные в культуре клеток |
US11292847B2 (en) | 2018-05-13 | 2022-04-05 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an IL-4R inhibitor |
WO2019225787A1 (ko) | 2018-05-24 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-b7-h3 항체 및 그 용도 |
US20210379146A1 (en) | 2018-10-04 | 2021-12-09 | Inserm (Institut National De La Santé Et De La Recherche Médigale) | Method to restore or improve cognitive functions |
CN111057721B (zh) * | 2018-10-12 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用 |
SG11202106049RA (en) | 2018-12-10 | 2021-07-29 | Amgen Inc | Mutated piggybac transposase |
MA55372A (fr) | 2019-03-21 | 2022-01-26 | Regeneron Pharma | Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie |
KR20220016139A (ko) | 2019-05-30 | 2022-02-08 | 암젠 인크 | 항체 이량체화를 유도하기 위한 경첩 영역 조작 |
MX2021015791A (es) | 2019-06-28 | 2022-04-01 | Amgen Inc | Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1. |
US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
MX2022001866A (es) | 2019-08-13 | 2022-03-11 | Amgen Inc | Muteinas de interleucina-2 para la expansion de celulas t reguladoras. |
EP4034556A1 (en) | 2019-09-26 | 2022-08-03 | Amgen Inc. | Methods of producing antibody compositions |
EP4054590A1 (en) | 2019-11-04 | 2022-09-14 | Amgen Inc. | Methods for treating leukemia |
MX2022005566A (es) | 2019-11-08 | 2022-07-19 | Amgen Inc | Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg. |
EP4061838A1 (en) | 2019-11-19 | 2022-09-28 | Amgen Inc. | Novel multispecific antibody format |
CA3162705A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
CA3164129A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
CA3191710A1 (en) | 2020-08-20 | 2022-02-24 | Amgen Inc. | Antigen binding proteins with non-canonical disulfide in fab region |
WO2022076474A2 (en) | 2020-10-07 | 2022-04-14 | Amgen Inc. | Rational selection of building blocks for the assembly of multispecific antibodies |
WO2022081824A1 (en) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
TW202233660A (zh) | 2020-10-30 | 2022-09-01 | 美商安進公司 | 過表現胰島素樣生長因子受體突變體以調節igf補充 |
WO2022103773A1 (en) | 2020-11-10 | 2022-05-19 | Amgen Inc. | Novel linkers of multispecific antigen binding domains |
CA3216559A1 (en) | 2021-04-20 | 2022-10-27 | Amgen Inc. | Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly |
EP4330281A1 (en) | 2021-04-29 | 2024-03-06 | Amgen Inc. | Methods for reducing low molecular weight species of recombinantly-produced proteins |
AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
WO2022261299A1 (en) | 2021-06-10 | 2022-12-15 | Amgen Inc. | Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3 |
TW202328442A (zh) | 2021-09-10 | 2023-07-16 | 美商安進公司 | 平臺宿主對igf—培養基之適應 |
AU2022361382A1 (en) | 2021-10-05 | 2024-03-28 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023129974A1 (en) | 2021-12-29 | 2023-07-06 | Bristol-Myers Squibb Company | Generation of landing pad cell lines |
WO2023172965A1 (en) | 2022-03-09 | 2023-09-14 | Amgen Inc. | Optimized transfection protocol |
WO2023175022A1 (en) | 2022-03-16 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to treat infectious diseases |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
US20240024472A1 (en) | 2022-05-02 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations |
WO2023215750A2 (en) | 2022-05-02 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4551433A (en) * | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
US4683199A (en) * | 1983-01-31 | 1987-07-28 | Sloan-Kettering Institute For Cancer Research | Interleukin-2 dependent cytotoxic T-cell clones |
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4675285A (en) * | 1984-09-19 | 1987-06-23 | Genetics Institute, Inc. | Method for identification and isolation of DNA encoding a desired protein |
PT83761B (pt) * | 1985-11-19 | 1989-06-30 | Schering Biotech Corp | Metodo para a producao de interleuquina-4 de mamifero |
KR900700132A (ko) * | 1988-02-02 | 1990-08-11 | 에릭 에스. 딕커 | 면역 글로불린 e 반응 억제 방법 |
GB8808015D0 (en) * | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5098833A (en) | 1989-02-23 | 1992-03-24 | Genentech, Inc. | DNA sequence encoding a functional domain of a lymphocyte homing receptor |
KR0172123B1 (ko) * | 1989-03-07 | 1999-02-01 | 게르하르트 후버; 루돌프 호프만 | 재조합 단백질 수용체 |
JPH04504061A (ja) * | 1989-09-07 | 1992-07-23 | シェリング・コーポレーション | インターロイキン―4レセプター |
US5246701A (en) * | 1990-10-05 | 1993-09-21 | Ludwig Institute For Cancer Research | Method for inhibiting production of IgE by using IL-9 inhibitors |
JPH07505047A (ja) * | 1991-11-27 | 1995-06-08 | シェリング・コーポレーション | ヒトインターロイキン−4受容体の細胞質ドメインの,il−4のアンタゴニストとしての部分 |
DE4322330A1 (de) | 1992-08-31 | 1994-03-03 | Behringwerke Ag | Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen |
CA2157785A1 (en) * | 1993-03-19 | 1994-09-29 | Immunex Corporation | Pharmaceutical compositions comprising soluble interleukin-4 receptor and interleukin-4 |
-
1989
- 1989-09-18 WO PCT/US1989/004076 patent/WO1990005183A1/en active IP Right Grant
- 1989-09-18 AU AU44113/89A patent/AU643427B2/en not_active Expired
- 1989-09-20 IL IL9170589A patent/IL91705A/en not_active IP Right Cessation
- 1989-09-21 IE IE302789A patent/IE61013B1/en not_active IP Right Cessation
- 1989-10-27 NZ NZ231189A patent/NZ231189A/en unknown
- 1989-10-31 ES ES89311244T patent/ES2103706T3/es not_active Expired - Lifetime
- 1989-10-31 DE DE68928043T patent/DE68928043T2/de not_active Expired - Lifetime
- 1989-10-31 JP JP1284660A patent/JP2744821B2/ja not_active Expired - Lifetime
- 1989-10-31 EP EP89311244A patent/EP0367566B1/en not_active Expired - Lifetime
- 1989-10-31 AT AT89311244T patent/ATE153068T1/de not_active IP Right Cessation
-
1990
- 1990-02-14 US US07/480,694 patent/US5840869A/en not_active Expired - Lifetime
-
1991
- 1991-04-29 DK DK199100784A patent/DK175583B1/da not_active IP Right Cessation
- 1991-04-29 FI FI912064A patent/FI106044B/sv active
-
1993
- 1993-07-20 US US08/094,669 patent/US5599905A/en not_active Expired - Lifetime
-
1995
- 1995-06-05 US US08/465,169 patent/US5717072A/en not_active Expired - Lifetime
- 1995-06-06 US US08/466,846 patent/US5856296A/en not_active Expired - Lifetime
- 1995-06-06 US US08/466,324 patent/US5767065A/en not_active Expired - Lifetime
-
1997
- 1997-07-30 GR GR970401920T patent/GR3024271T3/el unknown
-
1998
- 1998-06-15 US US09/094,917 patent/US6391581B1/en not_active Expired - Fee Related
-
2000
- 2000-11-28 US US09/724,901 patent/US6548655B1/en not_active Expired - Fee Related
-
2002
- 2002-03-22 US US10/104,590 patent/US6716587B2/en not_active Expired - Fee Related
-
2003
- 2003-10-17 US US10/688,495 patent/US7317090B2/en not_active Expired - Fee Related
-
2007
- 2007-11-20 US US11/986,376 patent/US20090226472A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE68928043D1 (de) | 1997-06-19 |
US6391581B1 (en) | 2002-05-21 |
US5717072A (en) | 1998-02-10 |
JP2744821B2 (ja) | 1998-04-28 |
DK78491D0 (da) | 1991-04-29 |
AU4411389A (en) | 1990-05-28 |
EP0367566A1 (en) | 1990-05-09 |
DE68928043T2 (de) | 1997-09-11 |
US6716587B2 (en) | 2004-04-06 |
IE61013B1 (en) | 1994-09-07 |
AU643427B2 (en) | 1993-11-18 |
IL91705A (en) | 1998-12-27 |
US7317090B2 (en) | 2008-01-08 |
DK78491A (da) | 1991-04-30 |
US5767065A (en) | 1998-06-16 |
ES2103706T3 (es) | 1997-10-01 |
US5856296A (en) | 1999-01-05 |
IL91705A0 (en) | 1990-06-10 |
US6548655B1 (en) | 2003-04-15 |
EP0367566B1 (en) | 1997-05-14 |
WO1990005183A1 (en) | 1990-05-17 |
US5840869A (en) | 1998-11-24 |
US5599905A (en) | 1997-02-04 |
ATE153068T1 (de) | 1997-05-15 |
FI912064A0 (fi) | 1991-04-29 |
US20090226472A1 (en) | 2009-09-10 |
US20030185821A1 (en) | 2003-10-02 |
DK175583B1 (da) | 2004-12-13 |
JPH02215385A (ja) | 1990-08-28 |
GR3024271T3 (en) | 1997-10-31 |
NZ231189A (en) | 1991-06-25 |
US20050118176A1 (en) | 2005-06-02 |
IE893027L (en) | 1990-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI106044B (sv) | Förfarande för framställning av en däggdjurs-IL-4-receptor (IL-4R) och dess motkropp och DNA som kodar för IL-4R, vektor och värdcell | |
FI116943B (sv) | Förfarande för framställning av fusionsproteiner innehållande receptor för tumörnekrosfaktor och DNA och vektor som kodar för dem | |
KR100467998B1 (ko) | Il-17수용체 | |
JP2753287B2 (ja) | インターロイキン―1受容体 | |
ES2227513T3 (es) | Nuevas citoquinas. | |
US5319071A (en) | Soluble interleukin-1 receptors | |
WO1989004838A1 (en) | Interleukin-1 receptors | |
FI103987B (sv) | Interleukin-7 | |
AU629958B2 (en) | Interleukin-7 receptors | |
IE903467A1 (en) | Granulocyte-colony stimulating factor receptors | |
JPH05500614A (ja) | 顆粒球コロニー刺激因子レセプター | |
US5223605A (en) | Interleukin-4 binding protein-γ | |
CA1340761C (en) | Interleukin-4-receptors | |
AU625534B2 (en) | Interleukin-1 receptors | |
NO309000B1 (no) | Isolert DNA-sekvens som koder for en pattedyr-IL-4-reseptor |